Galcanezumab in the Treatment of Migraine: A Narrative Review of Real-World Studies
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Galcanezumab in the Treatment of Migraine: A Narrative Review of Real-World Studies
Authors
Keywords
-
Journal
CLINICAL NEUROPHARMACOLOGY
Volume -, Issue -, Pages -
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2023-10-17
DOI
10.1097/wnf.0000000000000571
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score
- (2022) Luigi Francesco Iannone et al. CNS DRUGS
- Treatment satisfaction with calcitonin gene‐related peptide monoclonal antibodies as a new patient‐reported outcome measure: A real‐life experience in migraine
- (2022) Alba López‐Bravo et al. ACTA NEUROLOGICA SCANDINAVICA
- Real-world efficacy of galcanezumab for the treatment of migraine in Korean patients
- (2022) Soonwook Kwon et al. CEPHALALGIA
- Resumption of migraine preventive treatment with CGRP(-receptor) antibodies after a 3-month drug holiday: a real-world experience
- (2022) Bianca Raffaelli et al. JOURNAL OF HEADACHE AND PAIN
- CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients
- (2022) Francesca Schiano di Cola et al. NEUROLOGICAL SCIENCES
- Real-World Evidence — Where Are We Now?
- (2022) John Concato et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment Patterns for Calcitonin Gene-Related Peptide Monoclonal Antibodies Including Galcanezumab versus Conventional Preventive Treatments for Migraine: A Retrospective US Claims Study
- (2022) Oralee J Varnado et al. Patient Preference and Adherence
- Galcanezumab effect on “whole pain burden” and multidimensional outcomes in migraine patients with previous unsuccessful treatments: a real-world experience
- (2022) Marcello Silvestro et al. JOURNAL OF HEADACHE AND PAIN
- Conversion from chronic to episodic migraine in patients treated with galcanezumab in real life in Italy: the 12-month observational, longitudinal, cohort multicenter GARLIT experience
- (2022) Claudia Altamura et al. JOURNAL OF NEUROLOGY
- Real-World Trends in Characteristics of Patients with Migraine Newly Initiated on Erenumab in the USA: A Retrospective Analysis
- (2021) Juanzhi Fang et al. ADVANCES IN THERAPY
- Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)
- (2021) Fabrizio Vernieri et al. JOURNAL OF HEADACHE AND PAIN
- The impact of anti-CGRP monoclonal antibodies in resistant migraine patients: a real-world evidence observational study
- (2021) Marta Torres-Ferrús et al. JOURNAL OF NEUROLOGY
- Migraine: epidemiology and systems of care
- (2021) Messoud Ashina et al. LANCET
- Early Experiences in Switching between Monoclonal Antibodies in Patients with Nonresponsive Migraine in Spain: A Case Series
- (2021) Ignacio Patier Ruiz et al. EUROPEAN NEUROLOGY
- CGRP antibody therapy in patients with drug resistant migraine and chronic daily headache: a real-world experience
- (2021) Armin Scheffler et al. JOURNAL OF HEADACHE AND PAIN
- When should we consider chronic patients as non-responders to monoclonal antibodies targeting the CGRP pathway?
- (2021) Claudia Altamura et al. JOURNAL OF NEUROLOGY
- Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3‐month observational, longitudinal, cohort, multicenter, Italian real‐life study
- (2021) Fabrizio Vernieri et al. EUROPEAN JOURNAL OF NEUROLOGY
- Deterioration of headache impact and health-related quality of life in migraine patients after cessation of preventive treatment with CGRP(−receptor) antibodies
- (2021) Maria Terhart et al. JOURNAL OF HEADACHE AND PAIN
- Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months
- (2021) Edoardo Caronna et al. JOURNAL OF HEADACHE AND PAIN
- Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study
- (2021) Fabrizio Vernieri et al. JOURNAL OF HEADACHE AND PAIN
- Can real-world data really replace randomised clinical trials?
- (2020) Sreeram V. Ramagopalan et al. BMC Medicine
- Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial
- (2020) Wim M Mulleners et al. LANCET NEUROLOGY
- Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination
- (2019) Bianca Raffaelli et al. JOURNAL OF HEADACHE AND PAIN
- Non‐Responders to Treatment With Antibodies to the CGRP‐Receptor May Profit From a Switch of Antibody Class
- (2019) Christian Ziegeler et al. HEADACHE
- Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial
- (2018) Vladimir Skljarevski et al. CEPHALALGIA
- Real-world Evidence versus Randomized Controlled Trial: Clinical Research Based on Electronic Medical Records
- (2018) Hun-Sung Kim et al. JOURNAL OF KOREAN MEDICAL SCIENCE
- The Biology of Monoclonal Antibodies: Focus on Calcitonin Gene-Related Peptide for Prophylactic Migraine Therapy
- (2018) Bianca Raffaelli et al. Neurotherapeutics
- Evaluation of Galcanezumab for the Prevention of Episodic Migraine
- (2018) Virginia L. Stauffer et al. JAMA Neurology
- Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician
- (2018) Lawrence Blonde et al. ADVANCES IN THERAPY
- Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies
- (2018) Stefanie Förderreuther et al. JOURNAL OF HEADACHE AND PAIN
- Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
- (2018) Lars Jacob Stovner et al. LANCET NEUROLOGY
- Galcanezumab in chronic migraine
- (2018) Holland C. Detke et al. NEUROLOGY
- Calcitonin gene-related peptide and pain: a systematic review
- (2017) Wendy Sophie Schou et al. JOURNAL OF HEADACHE AND PAIN
- Real-world data in the United Kingdom: opportunities and challenges
- (2016) Laura McDonald et al. BMC Medicine
- Medication-overuse headache: risk factors, pathophysiology and management
- (2016) Hans-Christoph Diener et al. Nature Reviews Neurology
- Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine
- (2015) R. B. Lipton et al. NEUROLOGY
- Calcitonin Gene-Related Peptide: Physiology and Pathophysiology
- (2014) F. A. Russell et al. PHYSIOLOGICAL REVIEWS
- The Epidemiology of Primary Headache Disorders
- (2010) Matthew Robbins et al. SEMINARS IN NEUROLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started